|
|
Volumn 105, Issue 2, 2010, Pages
|
|
Redefining Personalized Medicine in the Postgenomic Era: Developing bladder cancer therapeutics with proteomics
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
CISPLATIN;
DOXORUBICIN;
METHOTREXATE;
VINBLASTINE;
BLADDER CANCER;
CANCER ADJUVANT THERAPY;
CANCER CELL;
CANCER INVASION;
CANCER SURGERY;
CANCER SURVIVAL;
CYSTECTOMY;
CYTOLOGY;
DRUG EFFICACY;
DRUG RESEARCH;
GENE EXPRESSION;
HUMAN;
MEDICINE;
MOLECULAR BIOLOGY;
NOTE;
PRIORITY JOURNAL;
PROSTATECTOMY;
PROTEOMICS;
TREATMENT RESPONSE;
URINALYSIS;
GENE EXPRESSION;
HUMANS;
INDIVIDUALIZED MEDICINE;
PROTEOMICS;
TUMOR MARKERS, BIOLOGICAL;
URINARY BLADDER NEOPLASMS;
|
|
EID: 74049136877
PISSN: 14644096
EISSN: 1464410X
Source Type: Journal
DOI: 10.1111/j.1464-410X.2009.09168.x Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|